Back to List/Filter


TRANSFORM-1

NCT04472598

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis (TRANSFORM-1)
Alfred Health (Haematology)
The Alfred, Commercial Road, Melbourne VIC, Australia
Recruiting
Primary Contact : Nola Kennedy, N.Kennedy@alfred.org.au , 03 9076 2217
Gosford Hospital (Haematology)
Holden St, Gosford NSW 2250, Australia
Recruiting
Primary Contact : Mark Lacey, Mark.Lacey@health.nsw.gov.au , 02 4320 3940
Liverpool Hospital (Haematology)
1 Campbell St, Liverpool NSW 2170, Australia
Recruiting
Primary Contact : Pinky Patel, pinky.patel@health.nsw.gov.au , 02 8738 9173
Peter MacCallum, Parkville Cancer Clinical Trials Unit (PCCTU) (Haematology)
Peter MacCallum Cancer Centre, Grattan Street, Melbourne VIC, Australia
Pending
Primary Contact : Enquiry Line Coordinator, clinicaltrials.enquiries@petermac.org , +613 8559 7456
Royal Perth Hospital (Haematology)
Victoria Square, Perth WA 6000, Australia
Recruiting
Primary Contact : Aida Morynko, Aida.morynko@health.wa.gov.au , +618 92241343
Secondary Contact : Lisa Forsyth, lisa.forsyth@health.wa.gov.au , +618 9224 8478
St Vincents Hospital, Sydney (Haematology)
Darlinghurst, Sydney, NSW
Recruiting
Primary Contact : Louise Christopherson, louise.christophersen@svha.org.au , 02 9355 5702

2020-000097-15M16-191

Interventional

Treatment - Drugs

Phase 3

18

100

09/11/2020

N/A

Open

By Specialist and/or Surgeon Referral

Any or not stated

No

No

No
Haematology
Myeloproliferative Disorders
Myelofibrosis
N/A

20110048